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Abstract 
 
Inflammatory Bowel Disease is a group of chronic gastrointestinal (GI) conditions for which 
therapeutic options are still insufficient. Although unpredictable, the TNBS-induced experimental 
model of colitis is widely used in preclinical testing. All components of the Renin-Angiotensin 
System are found in the gut. Angiotensin II (AngII) plays a role in many gut functions and in 
inflammation.  
The aim of this study was to refine the TNBS-induced model of colitis and to study the role of non-
neuronal cells in AngII-evoked colonic contraction. Male Wistar Han rats, 8-12 weeks old, were 
assigned to protocol 1 (30% ethanol/TNBS; tramadol; paracetamol in drinking water; 
metoclopramide) or 2 (21% ethanol/TNBS; paracetamol in honey-based solution; 
metoclopramide).  
Based on a Macroscopic Score, protocol 1 coursed 7 animals with Mild, 5 with Moderate and 7 
with Severe colitis, while protocol 2 resulted in 6 animals with Mild, 11 with Moderate and 2 with 
Severe colitis. In protocol 1, TNBS-induced animals with Mild and Moderate colitis recovered, 
respectively, food intake by day 4 and 6 and GI motility by day 3 and 5. In protocol 2, these 
animals recovered food intake by day 4 and 7, respectively, and those with Moderate colitis 
recovered GI motility by day 6. Rats with Severe colitis never recovered these parameters.  
Blocking Interstitial Cells of Cajal (ICC) decreased AngII-evoked colonic contraction in controls 
and in the distal colon of TNBS-induced animals. Hindering Enteric Glial Cells (EGC) also 
decreased AngII-evoked colonic contraction in TNBS-induced animals, but had no effect in 
controls.  
We conclude that protocol 2 decreases the rate of Severe colitis and confirm that the time-course 
of food intake and GI motility are good predictors of colitis outcome. Moreover, we uncovered that 
in physiological conditions, ICC, but not EGC, facilitate AngII-evoked colonic contraction, but that 
inflammation alters this non-neuronal regulation of AngII-evoked colonic contraction. 
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Resumo 
 
A Doença Inflamatória Intestinal é um grupo de doenças gastrointestinais crónicas, para as quais 
as opções terapêuticas são insuficientes. Apesar de imprevisível, o modelo experimental de colite 
induzida por TNBS é amplamente usado em testes pré-clínicos. Todos os componentes do 
Sistema Renina-Angiotensina são encontrados no intestino. A Angiotensina II (AngII) 
desempenha um papel em várias funções gastrointestinais e na inflamação. 
O objetivo deste estudo foi melhorar o modelo de TNBS e estudar o papel de células não-
neuronais na contração provocada pela AngII. Ratazanas macho Wistar Han, com 8-12 semanas 
de idade, foram distribuídos no protocolo 1 (30% etanol/TNBS; tramadol; paracetamol na água; 
metoclopramida) e 2 (21% etanol/TNBS; paracetamol no mel; metoclopramida). 
Com base num Score Macroscópico, o protocolo 1 cursou com 7 animais com colite Ligeira, 5 
com Moderada e 7 com Severa, enquanto que no protocolo 2 resultaram 6 animais com colite 
Ligeira, 11 com Moderada e 2 com Severa. No protocolo 1, animais induzidos com TNBS com 
colite Ligeira e Moderada recuperaram, respetivamente, a ingestão de alimento no dia 4 e 6 e a 
motilidade intestinal no dia 3 e 5. No protocolo 2, estes animais recuperaram a ingestão de 
alimento no dia 4 e 7, respetivamente, e aqueles com colite Moderada recuperaram a motilidade 
intestinal no dia 6. Ratazanas com colite Severa não recuperaram estes parâmetros. 
O bloqueio das Células Intersticiais de Cajal (ICC) diminuiu a contração induzida pela AngII em 
controlos e no colon distal dos animais induzidos com TNBS. O bloqueio das Células da Glia 
Entérica (EGC) também diminuiu a contração induzida pela AngII nos animais TNBS, mas não 
nos controlos. 
Concluímos que o protocolo 2 diminui a taxa de animais com colite Severa e confirmamos que o 
decurso temporal da ingestão de alimento e da motilidade gastrointestinal são bons preditores 
da colite. Além disso, descobrimos que, em condições fisiológicas, as ICC, mas não as EGC, 
facilitam a contração induzida pela AngII, mas que a inflamação altera esta regulação não-
neuronal da contração induzida pela AngII. 
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I. Introduction 
1. Inflammatory Bowel Disease – a growing worldwide burden 
Inflammatory Bowel Disease (IBD) is a group of chronic, relapsing and remitting inflammatory 
conditions of the gastrointestinal (GI) tract. They consist mainly of Ulcerative Colitis (UC) and 
Chron’s Disease (CD)1, 2 and are present in up to 0.5% of the general population in the western 
world3. According to the European Federation of Chron’s & Ulcerative Colitis Associations 
(EFCCA), IBD may affect as many as 5 million people worldwide4, of which over 3 million people 
live in Europe5. IBD is more common in developed than developing countries, but recently, many 
studies have reported increasing rates in previous low-incidence areas3, 6, 7. The estimated 
European annual cost of direct health-care of IBD was 4.6 to 5.6 billion euros in a 2013 review6. 
However, evidence suggests that indirect costs might exceed direct costs3. 
 
a. Clinical findings 
In UC, continuous and confluent (distal to proximal) inflammation is restricted to the rectum and 
colon, with erythema, erosions or ulcerations, crypt distortion, spontaneous bleeding, neutrophil 
infiltration, being mostly restricted to the mucosa. Traditionally, it results from a Th2-mediated 
response. Differently, in CD any region of the GI tract can be affected, and there is a transmural 
chronic inflammation with architectural abnormalities of the crypts, and a large number of acute 
and chronic inflammatory cells8. Also, it is frequently associated with strictures, fistulas and 
abscesses9. This disease has mainly a Th1-mediated response. Both UC and CD have also been 
shown to have a Th17 response8. 
Patients with IBD generally have melena or bloody stools, tenesmus, nocturnal defecation, weight 
loss and abdominal pain8. 
 
b. Etiology and pathogenesis 
Etiology and pathogenesis of IBD are complex and still not fully understood. Data suggest that it 
involves a combined and complex interaction between genetic and environmental factors that 
lead to dysfunction of the gut epithelial barrier and disregulation of the mucosal immune system 
and tolerance to the gut microbiome1, 10. More than 200 single-nucleotide polymorphisms have 
been associated with the risk of developing IBD. The importance of genetics is evident, but should 
be integrated with environmental factors (e.g. diet, medications, infections and lifestyle), which 
also directly influence the gut microbiome1, 9. Dysbiosis is observed in IBD patients, however, to 
date it is still unclear whether it is a cause or an effect of the inflammation (or both)1.  
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c. Current therapies 
Since IBD is a multifactorial disease, appropriate therapy is hard to define and therapeutic 
outcomes are highly variable. Currently, classical approaches for IBD treatment include 
aminosalicylates (e.g. mesalazine), antibiotics, probiotics, corticosteroids (e.g. hydrocortisone; 
prednisolone), thiopurines (e.g. azathioprine; mercaptopurine), methotrexate, several biologic 
drugs (e.g. infliximab; vedolizumab), and surgery10. The choice of treatment and administration 
route depends on the severity and extension of the disease, as shown in Figure 1 
 
 
Since IBD is a chronic condition, long-term treatment is needed. Many of these drugs act as 
immunossupressants, which is not ideal for long-period therapy. Thus, the need for more efficient 
and safer therapeutic options arise. The more extensive research on molecular pathways of 
disease have led to new emerging therapies, generally called biologicals, such as anti-TNF, anti-
adhesion and anti-IL12/23 agents. Also, drugs commonly used for other indications are being 
investigated and can have an important role in IBD treatment11.  
 
d. The 2,4,6-Trinitrobenzene Sulfonic Acid-induced model of colitis 
The advance in knowledge of the pathophysiology of IBD was, in part, prompted by the 
development and use of several animal models of IBD. These are usually divided in 4 groups: (i) 
genetically engineered; (ii) immune-manipulated; (iii) spontaneous; (iv) erosive/chemical. Within 
the latter, the 2,4,6-trinitrobenzene sulfonic acid (TNBS) and dextran sulfate sodium (DSS) 
models are the most widely used in rodents, due to their simplicity, inexpensiveness and 
reproducibility8. 
The TNBS model was first itroduced by Morris et al., in 1989, in rats. Since then, several variations 
and modifications of the original protocol have been described and nowadays lack 
standardization. The induction of colitis is accomplished through an intrarectal instillation of an 
ethanolic solution of TNBS13. Ethanol is used to disrupt the mucosal barrier, enabling TNBS to 
translocate to the submucosal layer where it haptenizes amino groups of colonic and bacterial 
proteins, signalling them as targets of the host immune system8. After induction, animals present 
diarrhea, rectal bleeding, body weight loss, piloerection, loss of grooming and decreased general 
activity. Macroscopically, it causes mucosal edema, wall thickness, distortion of crypts and 
Figure 1 - Therapeutic approaches in IBD. 
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ulceration. The cytokine profile seen in this model is a Th1 and Th17 profile8, 13. This model mimics 
many features of IBD and is widely used for preclinical testing of many treatment strategies and 
to study features of immunity, pathology and microbial importance in both acute and chronic CD8, 
14. Despite being a relatively reproducible model, broad variations in disease outcome are 
reported. It is known that animal strain, species, age, housing conditions, percentage of 
ethanol/TNBS dose and the technical induction protocol can be responsible for this variability. 
However, individual characteristics might also play an important role, since animals undergoing 
the same technical protocol and dosing also develop different onset and disease outcomes13. 
Unfortunately, researchers recurrently fail to fully describe the protocol for induction of 
experimental models. Standardization of protocols and correspondent description would allow to: 
(i) increase reproducibility; (ii) accurately interpret results and compare different studies; (iii) 
indirectly reduce the number of animals used15. 
In a previous protocol described by our group, we were able to categorize TNBS-induced animals 
by disease outcome based on a Macroscopic Score, which was then confirmed by histological 
evaluation. Moreover, animal categorization was able to be predicted, ante-mortem, by the time-
course of food intake and fecal pellet excretion. In this previous protocol, animals were induced 
with a 30% ethanolic solution of TNBS (20 mg/rat) and analgesia was provided with tramadol (10 
mg/kg, SC, only on day 0) and with paracetamol in drinking water along the induction protocol16. 
 
2. The Enteric Nervous System 
In order to better understand the pathophysiology of IBD, it is crucial to comprehend the 
physiology of the gut in health and disease, which includes a complex interaction between smooth 
muscle cells (SMC), epithelial cells, the enteric nervous system and the external environment. 
The Enteric Nervous System (ENS) plays an important role in gut motility, nutrient absorption, 
mucus secretion, vascular blood flow and wound healing. It is organized in two major plexuses: 
the myenteric or Auerbach’s plexus (between the circular and longitudinal muscular layers) and 
the submucosal or Meissner’s plexus (between the submucosa and the mucosa) - complex 
networks of enteric neurons that interact closely with glial cells and Interstitial Cells of Cajal 
(ICC)17, 18. 
Over 30 neurotransmitters have been described, such as acetylcholine (ACh), noradrenaline, 
ATP and its metabolites, nitric oxide (NO) and gamma-aminobutyric acid17, 19. ACh is the major 
excitatory neurotransmitter in the ENS, activating auto-receptors and directly stimulating SMC, 
but also regulating the release of other neurotransmitters20. ATP or related nucleotides (through 
purinergic receptors) and NO are two of the major non-adrenergic non-cholinergic inhibitory 
neurotransmitters in the gut21, 22. 
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a. Role of the Interstitial Cells of Cajal 
ICC are known to be the pacemaker cells for slow wave activity in the GI tract, which are 
responsible for spontaneous contractions23. These cells are in tight association with excitatory 
and inhibitory motor neurons, SMC24 and platelet-derived growth factor receptor (PDGFR)α+ 
cells25. ICC connect with SMC and PDGFRα+ cells through gap junctions, forming the SIP 
syncytium, which receives inputs from motor neurons from the myenteric plexus25. SMC were 
once considered the main targets of motor neurons, but now it is known that ICC and PDGFRα+ 
cells are crucial for mediating GI motility25. In fact, it has been suggested that there are more 
nerve-ICC-IM than nerve-SMC contacts25. In the colon, ICC are organized in three networks: 
Myenteric plexus ICC (ICC-MY), Submucosal Plexus ICC (ICC-SMP)26 and Intramuscular ICC 
(ICC-IM)23. In mice, ICC are mostly distributted in the proximal than in the distal colon27. A 
combined interaction of Anoctamin-1 (a calcium-activated chloride channel; ANO1) and voltage-
gated T-type Ca2+ channels is suggested to generate the pacemaker activity of colonic ICC, in 
mice28–30. Studies have shown that ICC can mediate nitrergic23, 31 and purinergic relaxation21, as 
well as cholinergic contraction25 of the GI smooth muscle. In humans, ICC-SMP are proposed to 
be the pacemakers of the longitudinal and circular muscle layers and are found to have 
ultrasturtural changes in both CD and UC patients32. All types of colonic ICC showed morphologic 
and quantitative alterations in UC patients33 . Whether this is a cause or consequence of the 
disease is still not understood.  
 
b. Role of Enteric Glial Cells 
Enteric Glial Cells (EGC) are similar to astrocytes in the Central Nervous System (CNS), and 
outnumber enteric neurons, being in direct contact with these cells and with all the other cell types 
in the gut wall17. They are divided in four groups, acoording to their location: mucosal, 
submucosal, myenteric ganglia and muscular18. Only recently researchers suggested the 
involvement of EGC in the control of all major GI functions (structural support, neurotransmitter 
modulation, motility, epithelial function and integrity17), accomplished in part by being capable of 
phenotypic changes under extrinsic signals (reactive gliosis)17. Direct activation of EGC is enough 
to produce neurogenic reflexes, controlling motility and secretions34. Oppositely, disrupting these 
cells have shown to decrease GI motility, in mice35. Neuro-glial communication in the GI system 
is not as well understood as in the CNS18. However, it is known that they are equipped with 
receptors for various endogenous neurotransmitters, such as ACh, ATP and serotonin18, 21. These 
cells respond to injury, stress and inflammation36 and are able to produce both pro-inflammatory 
and anti-inflammatory responses, depending on the type of stimuli37. Interestingly, GFAP (a 
marker of glial reaction) is overexpressed in colonic biopsies of inflamed areas in CD patients, 
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whereas non-inflamed areas show a decreased expression of this marker, compared to controls36. 
Moreover, TNBS induced mitosis of myenteric EGC has been shown in the guinea-pig ileum38. 
Therefore, it is suggested that EGCs play a major role in IBD.  
 
3. The Renin-Angiotensin System 
Classically, renin cleaves angiotensinogen, to produce Angiotensin I. This 10-aminoacid peptide 
is further cleaved into the 8-aminoacid peptide, Angiotensin II (AngII), by the Angiotensin 
Converting Enzyme (ACE). This enzyme also inactivates bradykinin. AngII is the classical final 
product of the Renin-Angiotensin System (RAS) and is a potent vasoconstrictor, decreases the 
excretion of salt and water by the kidney (promoting the secretion of aldosterone), thus incresing 
arterial pressure39. AngII exerts these actions, as well as hypertrophy, inflammation and fibrosis, 
by activating the AngII AT1 receptor subtype (AT1R). However, activation of the AngII AT2 receptor 
subtype (AT2R) usually counteracts AT1R-mediated effects. Recently, many other enzymes and 
molecules related to the system have been discovered40 but are not the focus of the present work. 
Although this system is mainly characterized in the cardiovascular and renal systems and 
associated pathologies, it is also expressed in many organs, such as brain, liver, reproductive 
organs, and also the GI tract40. The presence of all RAS components in the GI tract suggests that 
AngII can be produced locally, influencing GI function. 
 
a. Renin-Angiotensin System in Inflammatory Bowel Disease 
All RAS components are present in the GI tract40. In the human colon, both AT1R and AT2R have 
been described in mucosal samples,41 crypt bases,40 vessel walls, myofibroblasts and 
macrophages of the lamina propria42. Moreover, AT1R have been detected in SMC of the circular 
and longitudinal muscle40 and AngII have also been suggested to cause contraction by acting 
directly on these cells, in vitro40, 43. A study using human and guinea pig small intestine showed 
that AngII promoted an excitatory action in myenteric and submucosal plexuses exclusively by 
activating AT1R, which were present in 65-70% of neurons41. Other studies show that AngII plays 
other physiological roles in the gut, as AT1R-mediated stress-induced gastric injury 44 and AT2R-
mediated duodenal alkaline secretion45. Activation of AT1R by AngII also facilitates the release of 
neurotransmitters, such as tachykinins and ACh in the colon46.  
AngII induces pro-inflammatory effects such as increase in vascular permeability and recruitment 
of inflammatory cells and, as so, some researchers have started to study RAS in the context of 
IBD. Studies using AT1R antagonists47, 48 and ACE inhibitors49 have shown to be beneficial in 
TNBS-induced colitis outcome. However, in those studies using AT1R antagonist, drug 
administration started before TNBS induction, making it unclear whether beneficial results were 
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due to a prophylatic or therapeutic action. Inokuchi et al., also showed that angiotensinogen gene 
knockout mice had a less severe colitis and impaired pro-inflammatory cytokine production after 
TNBS induction, compared to wild-type mice50. In previous works of our group16, AT1R have been 
shown to mediate AngII colonic contraction in both controls and TNBS-induced rats. However, 
contrarily to what others have reported51, AT2R did not counteract AT1R-mediated contraction in 
TNBS-induced animals, although this mechanism was operating in controls16. Our data on 
mechanistic pathways also suggests a role for a prejunctional pathway mediating AngII-induced 
contraction along the colon of both control and TNBS-induced rats. This prejunctional pathway is 
inhibitory since Tetrodotoxin (TTX) markedly increased AngII-mediated contractions and NO was 
identified as a possible mediator of this inhibition16. Furthermore, neither purinergic nor adrenergic 
pathways influenced AngII-mediated contraction (unpublished data).  
In human IBD, Jaszewski et al., found that AngI and AngII levels correlated with Chron’s Disease 
Activity Index52. Also, IBD patients on AT1R antagonist therapy have less expression of 
proinflamamtory cytokines53. In addition, cell apoptosis and Th17 responses are promoted by AngII 
in human colitis53. Components of the alternative RAS, such as Ang(1-7) (converted from AngII 
by ACE240) and ACE2 itself have also been shown to be upregulated in IBD patients42. These 
data suggest that the RAS might have a role in inflammation and fibrosis in IBD42, 52 
 
Aims 
This study had two different but interlinked aims. First, we aimed to refine the TNBS-induced 
model of colitis in rats in order to decrease the percentage of TNBS-induced rats developing 
Severe colitis. Also, we wanted to confirm whether the time-course of food intake and fecal 
excretion are good predictors of colitis severity. Second, we aimed to further characterize the 
mechanistic pathways activated by AngII to cause colonic contraction, by testing the role of non-
neuronal cells (ICC and EGC). In line with previous works from our research group, we studied 
three portions of the TNBS-induced rat colon: Proximal Colon (PC), Upstream Distal Colon (UDC) 
and Terminal Distal Colon (TDC) – and compared the results with the same regions of the colon 
of control rats. 
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II. Materials and methods 
1. Animals and housing 
Animals were raised and maintained in the rodent animal house facility of ICBAS-UP (approved 
by the national competent authority: 024159/2017-DGAV). According to the EU Directive 2010/63 
and the Portuguese DL 113/2013, the project was approved by the local (179/2017-ORBEA-
ICBAS-UP) and national (003511/2018-DGAV) competent authorities, the severity of the 
procedure was estimated as being moderate and the study was reported in accordance with the 
ARRIVE Guidelines. No animal was used specifically for the purpose of refining the TNBS-
induced colitis model (Reduce). Since we had a functional ongoing study, we decided to refine 
the animal model, increasing the scientific knowledge without increasing the animal effort. 
Fifty-five male Wistar Han rats were raised and housed in the laboratory animal facility of ICBAS-
UP. Littermates were housed in groups of 2 or 3 in Sealsafe Plus GR900 cages, with Corncob 
ultra 12 bedding (Ultragene) and were given access to a laboratory rodent diet (4 RF 21, 
Mucedola S.r.I., Italy) and to autoclaved tap water ad libitum. They were submitted to a 12-hour 
light/dark cycle with controlled ventilation, temperature (20-24ºC) and relative humidity (40-60%). 
As enrichment, polycarbonate or paper tunnels and different seeds or sugar-free cereal flakes 
were placed in every cage. Also, nesting paper material was provided daily. Animals were used 
with 8-12 weeks of age. 
 
2. Colitis induction and analgesia  
On day -1 all animals were fasted for 24 hours, in individual cages, and were given access to both 
autoclaved tap water and to a 5% sucrose solution to avoid the decrease in blood glucose during 
this period54. The purpose of this period was to empty the GI tract, facilitating the contact between 
the ethanolic solution of TNBS and the colonic mucosa. 
The following day (day 0) animals were randomly allocated to control or TNBS-induced groups. 
Those of the TNBS groups were anesthetized, ad effectum, with isoflurane (Isoflo®, Esteve). 
While anesthetized, 250 µL of an ethanolic solution of TNBS (20 mg/rat) was rectally instilled 
using a 7.6 cm ball-tipped needle. Metoclopramide (Metoclopramida 10 mg/2mL, Labesfal) at a 
dose of 0.8 mg/kg, SC, was administered to both TNBS groups the next day (day 1), to enhance 
intestinal motility. Controls did not undergo any of these procedures. 
Animals were divided in two protocols: (i) protocol 1: Controls (n=9) and TNBS-induced animals 
(n=19); (ii) protocol 2: Controls (n=8) and TNBS-induced animals (n=19), which differed in 
induction and analgesia.  
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In protocol 1, animals were induced with a 30% ethanolic solution of TNBS and forelimbs were 
lightly raised until anesthesia recovery. Analgesia was provided to the TNBS group with tramadol 
(Tramadol 100 mg/2mL, Labesfal; a weak µ-opioid receptor agonist and inhibitor of neuronal 
reuptake of norepinephrine and serotonin55) on day 0 (soon after TNBS induction), at a dose of 
10 mg/kg, SC. Also, paracetamol (Paracetamol 40 mg/ml, Farmoz) was administered in the 
drinking water (2 mg of paracetamol per ml of drinking water) until the end of the experiment. 
Controls of this protocol weren’t given any drug. 
Since the outcome of colitis was not improved with protocol 1 when compared to that of the 
previous protocol used by our group, a new protocol was tested (protocol 2). In this protocol, 
animals were induced with a 21% ethanolic solution of TNBS and were held in a vertical position 
for 60 seconds to spread the TNBS solution more uniformly in the distal colon, and to minimize 
extravasation. Analgesia was provided to the TNBS group, with paracetamol (500 mg/kg, per os), 
daily, in a honey-based solution (300 µL). These animals were also given the same amount of 
honey, without paracetamol, the day before TNBS induction. Tramadol (same dose as in protocol 
1) was only given if animals presented evident signs of pain or discomfort. The control group of 
this protocol only received honey throughout the experiment. 
 
3. Animal assessment and welfare evaluation 
All animals were daily monitored (from 10h00 to 13h00) since day -1 to day 7 or 8. Simple and 
objective parameters were quantified every day: fluid and food intake, number, weight and 
consistency of fecal pellets and body weight. Also, to assess animal welfare, rats were scored by 
cage-side assessment using two simple scoring sheets: general welfare/clinical signs (GW; Table 
1) and the Rat Grimace Scale (RGS; Table 2), which uses facial expressions as signs of 
pain/discomfort, applied in real-time. Apart from this assessment, other known indicators of pain 
in rats were analyzed and noted when present, such as decreased appetite, “hunch” posture 
(associated with abdominal pain) and other abnormal postures, porphyrin secretions and rapid 
shallow breathing56. These scores were attributed before handling, to avoid masking pain signs 
(stress-induced analgesia). 
Table 1 - General welfare score sheet. 
General welfare/clinical signs score  Score 
Normal posture, coat and activity 0 
Reduced activity; piloerection; dehydration <5% 1 
Hypokinesia; Reduced grooming; Piloerection; CDR; dehydration 5-8% 2 
Hypokinesia; Abnormal posture (kyphosis); Piloerection; CDR; dehydration >8% 3 
Inactive. Kyphosis. Non-responsive 4 
CDR – chromodacryorrhoea. 
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Table 2 - Rat Grimace Scale. 
Rat Grimace Scale 0 – “not present” 1 – “Moderately present” 2 – “Obviously present” 
Orbital tightening 
Narrowing of the orbital area; tightly closed eyelid; eye squeeze (contracted 
orbital muscles); Nictitating membrane may be visible. 
Nose/cheek 
flattening 
Flattening and elongation of the bridge of the nose and flattening of whisker 
pads; Absence of the crease between whisker pads and cheeks. 
Ear change (position, 
orientation and shape) 
Ears fold, curl inwards (giving a pointed shape) and are angled forward or 
outward; The space between ears appear wider. 
Whisker changes 
Whiskers angled back, along the head, and directed outwards; Whisker look 
closer together and are less distinct. 
adapted from NC3Rs RGS Manual57 
 
4. Macroscopic Evaluation 
On day 7 or 8 post-TNBS induction, all animals were euthanized by decapitation, in a separate 
room. The abdomen was opened, and the general appearance of the colon and surrounding 
tissues was observed to evaluate the presence of adhesions to adjacent tissues. The colon was 
then carefully excised, cleaned of colon content using Krebs-Henseleit solution, measured and 
weighed. Afterwards, four 1-cm segments of the colon (orange in Figure 2) were cut for further 
functional study. These segments represent the proximal colon (PC), upstream distal colon (UDC) 
and terminal distal colon (TDC).  
 
As also seen in Figure 2 (in blue), two other portions also representing the UDC and TDC, were 
opened through the mesenteric border and given an individual Macroscopic Score (MaS), by two 
independent observers, according to Table 3. The animal categorization was defined as the mean 
of the MaS of both tissues. As previously suggested by our group, TNBS-induced rats were 
categorized, according to the MaS, as having Mild colitis (MaS=]0-4[), Moderate colitis (MaS=[4-
8[) or Severe colitis (MaS=[8-12])16. 
Figure 2 - Different portions of the colon used in the protocol. MaS – colonic portions used for Macroscopic Scoring (in 
blue); portions used for the functional study (in orange): TDC (terminal distal colon); UDC (upstream distal colon); PC 
(proximal colon). 
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Table 3 - Macroscopic Scoring Parameters. 
Macroscopic 
Scoring Parameters 
Adhesions to 
adjacent organs 
Colon thickness 
Mucosal 
edema/hyperemia 
Mucosal 
ulcers 
Score 
0 Absent Normal Absent Absent 
1 Mild / focal Mild Mild Single 
2 Moderate / zonal Moderate Moderate At one site 
3 Severe / diffuse Marked increase Severe At more sites 
 
5. Functional study 
In this part of the study, controls were compared to all TNBS-induced rats as a single group (not 
discriminating categories of colitis) in order to reduce the number of animals used for scientific 
purposes. However, only TNBS-induced rats that evolved to Mild or Moderate colitis were used 
because they mimic the majority of IBD patients and TNBS-induced animals that developed 
Severe colitis showed very low contractile capacity (previous works)16. 
The four 1-cm long portions of the colon were individually mounted along their longitudinal axis, 
in 10mL organ baths with oxygenated (95% O2; 5% CO2) Krebs-Henseleit solution at 37±1ºC. 
Tissues were fixed to isometrical transducers (UGO BASILE S.R.I., Italy, Model 7004) and 
stretched passively to an initial tension of 1 gram. The responses were recorded on a PowerLab 
system. The experimental protocol is shown in Figure 3 
 
The concentration of AngII added to each portion was submaximal (previously determined16): 
100nM for TDC, 30nM for UDC and 10nM for PC. After the first stimulus with AngII, the tissues 
were washed every 10 minutes for a 1-hour period to avoid desensitization of AngII receptors. 
After, NNC 55-0396 (10 µM for PC; 30 µM for UDC and TDC) or Fluorocitrate (300 µM) were 
incubated for 20 minutes. Afterwards, without washing, the same concentration of AngII was 
Figure 3 - Experimental protocol used to study the reactivity of the rat colon to Angiotensin II in the absence and 
presence of NNC 55-0396 and Fluorocitrate. ACh – acetylcholine; KCl - Potassium chloride. 
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added to each portion. At the end of the functional protocol, all tissues were stimulated with 
sodium chloride (KCl) 125 mM to register the maximum response. Finally, tissues were weighed 
and left overnight at room temperature, on a filter paper, to be weighed after drying. 
 
6. Statistical analysis  
All data are presented as Mean(SD). The statistical analysis was performed by paired/unpaired 
Student’s t-test, one-way or 2-way ANOVA, followed by Tuckey’s multiple comparisons test, and 
the Chi-square test, as needed. Paired Student’s t test was used to compare the response to 
AngII in the absence and in the presence of an antagonist, in the same colonic sample. One-way 
ANOVA followed by Tuckey’s multiple comparisons was used to compare between controls and 
the 3 colitis categories of TNBS-induced rats within the same protocol. The two-way ANOVA was 
used to look for interactions between the two factors tested. The Chi-square test was used to 
compare the % of rats allocated to each TNBS-induced category of colitis. A p<0.05 was 
considered statistically significant. 
 
7. Drugs 
The Krebs-Heinselet solution (in mM): 118 NaCl; 4.8 KCl; 2.5 CaCl2 • 2H2O; 1.2 NaH2PO4 • H2O; 
1.2 MgSO4 • 7H2O; 25 NaHCO3-; 0.02 EDTA-Na2; 0.3 Ascorbic acid; 11 monohydrated glucose. 
Drugs used in the functional study were dissolved in distiled water to desired concentration and 
stored at -20⁰C, except Fluorocitrate which was prepared as described by Paulsen et al58. The 
vehicle of the fluorocitrate solution was also used in the functional study to see whether the 
solution itself could affect tissue response. 
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III. Results and Discussion 
Part I: 2,4,6-Trinitrobenzene Sulfonic Acid-induced model of colitis: time-
course and comparison between 2 protocols of induction 
1. Macroscopic Evaluation and Colitis outcome 
According to our previously suggested colitis categorization based on the MaS (Table 3)16, in 
protocol 1, there was a uniform distribution of TNBS-induced rats across the three categories of 
colitis severity (Table 4). As for protocol 2, that distribution was statistically different, with more 
animals evolving with Mild and Moderate colitis than with Severe colitis (Table 4). These results 
suggest that protocol 2 represents a refinement for the TNBS-induced model of colitis.  
 
Table 4 – Number (%) of rats in each category of TNBS-induced colitis in the 3 protocols. 
* Data from Ferreira-Duarte, M.16  
 
The first explanation for this result might be the difference in the percentage of ethanol. In this 
animal model, ethanol is used to disrupt the mucosal barrier and allow TNBS to translocate to the 
submucosal layer and cause inflammation8. Therefore, we can deduce that the reduction in the 
percentage of TNBS-induced animals developing Severe colitis in protocol 2 can be due to the 
reduction of the % of ethanol in the instilled solution. Second, the differences in analgesia might 
have also contributed to this result. Paracetamol is known to be less toxic and to be effective in 
producing analgesia in rats, but less effective than opioids. In the previous protocol and in protocol 
1, paracetamol was self-administered, which reduces stress59. However, as reported in other 
studies, our animals preferred the water bottle rather than the paracetamol solution bottle59. Since 
we also observed a high variability in the consumption of the latter, effective analgesia could not 
be guaranteed to all animals. Factors like neophobia and degree of pain can explain these 
variations. Regarding tramadol administration, although it has a smaller effect on GI motility when 
compared to other opioids55, the use of this analgesic was questioned in protocol 2, since we 
stated that restoration of GI motility is related with the colitis outcome16. Therefore, in protocol 2, 
paracetamol was daily administered, per os, at a dose of 500 mg/kg60 in a honey-based solution. 
Although minimal stress was induced by handling and restraint for the administration of 
paracetamol, a correct and effective dose was able to be guaranteed to all animals. A further 
 
Mild colitis 
MaS=]0-4[ 
Moderate colitis 
MaS=[4-8[ 
Severe colitis 
MaS=[8-12] 
p value 
Previous Protocol * 5 (29.4%) 6 (35.29%) 6 (35.29%) 0.9155 
Protocol 1 7 (36.84%) 5 (26.31%) 7 (36.84%) 0.7292 
Protocol 2 6 (31.58%) 11 (57.89%) 2 (10.53%) 0.0081 
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refinement of this protocol would be the introduction of a training period for this procedure. 
Tramadol, at the same dose as in protocol 1, was only given once to 5 animals, of which only one 
was categorized as having Severe colitis. One can hypothesize that the effective reduction of pain 
in protocol 2 could have helped the restoration of GI motility, therefore reducing the severity of 
colitis. Third, it is reasonable to suggest that honey might have played a role in these results, due 
to its antioxidative and anti-inflammatory properties61. Many studies using different animal models 
of IBD have shown beneficial effects of honey, or its components, in the outcome of disease61–63. 
However, the amount of honey administered to our rats was substantially lower (1 mL/kg, daily) 
than those usually reported. Finally, the method of induction (raised forelimbs vs. vertical position 
for 60 seconds) could also have contributed to these results. On the day post-TNBS induction 
(day 1), animals from protocol 2 generally appeared to have less TNBS on nesting paper, 
suggesting that less TNBS was lost. Therefore, oppositely to what was observed, it would be 
expected that more animals would experience a Severe colitis in this protocol. A possible 
combination of the first three explanations might have contributed to this refinement. 
The mortality rate in protocol 1 and 2 was 1/28 (3.6%) and 0/27 (0%), respectively. In the previous 
protocol it was 0/28 (0%)16. The animal of protocol 1 died on day 6; free abdominal liquid was 
found in the necropsy and the animal was classified as having a Severe colitis. 
The colon of TNBS-induced animals was filled with pasty stools and many times adhered to 
adjacent organs of the abdominal cavity, opposite to control animals for which colonic content 
consisted of ovoid-shaped fecal pellets and no adhesions were seen. 
Oppositely to our results with the previous protocol16, the partial MaS of TDC and UDC was similar 
between colonic regions, both in protocol 1 (Figure 4A) and in protocol 2 (Figure 4B), which 
indicates that these two portions were equally affected by TNBS. The method of induction might 
have contributed to this result. Anyway, the mean MaS progressively increased across  categories 
of colitis severity, in protocols 1 and 2 (Figure 4C and Figure 4D, respectively). We highlight that 
TNBS-induced animals with Moderate colitis had generally higher scores in protocol 2 than in 
protocol 1. 
After carefully excising the colon, it was cleaned with the Krebs-Henseleit solution, measured and 
weighed. With these measures, we calculated the Weight-to-Length (WL) ratio for every animal, 
which is considered an indirect index of inflammation, since inflammation causes thickening and 
consequent shortening of the colon64. In protocol 1 (Figure 5A), TNBS-induced animals with 
Severe colitis had higher WL ratio than the other 3 groups, and those with Moderate colitis had 
higher WL ratio than controls. As for protocol 2 (Figure 5B), TNBS-induced rats with Moderate 
and Severe colitis had higher WL ratio than both controls and animals who developed Mild colitis. 
Our results suggest that animals with higher severity of colitis also had a more marked underlying 
inflammatory reaction, which probably results in cell hypertrophy, fibrosis and edema. Also, the 
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higher WL ratio of TNBS-induced rats with Moderate colitis in protocol 2, compared to protocol 1, 
might be explained by the generally higher MaS of these animals, reflecting more marked 
inflammatory reaction. 
 
 
The perimeter of the portions not used for the functional study was measured afterwards. Colonic 
perimeter was calculated by the mean of the perimeters of the three portions. In protocol 1 (Figure 
5C), TNBS-induced animals with Severe colitis had higher colonic perimeter than the other 
groups. In protocol 2 (Figure 5D), TNBS-induced rats with both Moderate and Severe colitis had 
higher colonic perimeter than the other two. This agrees with what was observed in the necropsy 
of the animals, where animals with Severe colitis showed a marked distension of the colon. Once 
again, the higher perimeter of TNBS-induced rats with Moderate colitis in protocol 2 might be 
explained by the higher MaS of these animals, which indicates a higher severity of colitis. 
Comparison of these two parameters with the previous protocol is not possible due to different 
measurement method. 
Figure 4 – General Macroscopic Score of UDC and TDC in protocol 1 (A) and 2 (B); Mean 
Macroscopic score according to group, in protocol 1 (C) and 2 (D). *p<0.05 vs. Controls; #p<0.05 vs. 
Mild Colitis; $p<0.05 vs. Moderate Colitis. 
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2. Predictors of TNBS-induced colitis severity 
In the previous protocol, the time-course of food intake and number of fecal pellets were 
considered good predictors of colitis outcome. Therefore, we further investigated these two 
parameters, in addition with body weight change, fluid intake, Rat Grimace Scale (RGS) and 
General Welfare (GW) scores.  
 
a. Fasting period 
Animals were fasted in the same conditions and were only randomly assigned to the groups 
afterwards. As expected, no differences were found in fecal pellet weight, % of body weight loss 
and fluid intake between any group (data not shown). 
 
Figure 5 - Weight-Length ratio (g/cm) according to groups, of protocol 1 (A) and 2 (B); Colonic perimeter 
(mm) in protocol 1 (C) and 2 (D). *p<0.05 vs. Controls; #p<0.05 vs. Mild Colitis; $p<0.05 vs. Moderate 
Colitis. 
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b. Food Intake 
The food intake along the experimental period of both protocol 1 and 2 is depicted in Figure 6A 
and 6B, respectively.  
 
The time-course of food intake showed that food intake decreased significantly in all TNBS groups 
of both protocols in the first 48 hours post-induction with TNBS comparing to the corresponding 
control group. Also, in both protocols, TNBS-induced rats with Mild colitis registered the lowest 
food intake on day 2, but then restarted to eat and normalized food intake by day 4, when 
compared to controls. For both protocols, TNBS-induced rats with Moderate and Severe colitis 
registered the lowest food intake on day 2 and 3. Then, TNBS-induced rats with Moderate colitis 
started to eat on day 4 and, those on protocol 1 normalized food intake by day 6, while those on 
protocol 2 almost normalized food intake by day 7. Differently, TNBS-induced rats with Severe 
colitis never regained normal food intake. In our previous protocol16, TNBS-induced rats with Mild 
and Moderate colitis normalized food intake by day 5 and 6, respectively. 
In agreement with this pattern, in protocol 1 the Area Under Curve (AUC) for food intake (Figure 
6C) was progressively lower in TNBS-induced rats with Mild>Moderate>Severe colitis than in 
control rats. Differently, in protocol 2, the AUC for food intake (Figure 6D) of all TNBS-induced 
Figure 6 - Time-course of food intake (g) in protocol 1 (A) and 2 (B); controls (circles); Mild Colitis 
(squares); Moderate Colitis (triangles); Severe Colitis (inverted triangles). Area Under Curve of food 
intake (g.day) in protocol 1 (C) and 2 (D). *p<0.05 vs. controls; #p<0.05 vs. Mild Colitis; $p<0.05 vs. 
Moderate Colitis. 
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rats was lower than that of controls, and that of TNBS-induced rats with Moderate and Severe 
colitis was also lower than that of TNBS-induced rats with Mild colitis. 
 
c. Body weight 
The body weight change was analyzed as a variation from that measured after the fasting period 
(initial weight). The time-course of body weight change for protocol 1 and 2 are presented in 
Figure 7A and 7B, respectively. 
 
In protocol 1, all TNBS groups lost weight in the 72 hours post-TNBS induction. Since then, TNBS-
induced rats with Mild colitis regained body weight from day 4 onwards so that, by day 7 they had 
regained their initial weight. As for TNBS-induced rats with Moderate colitis, they only started to 
regain weight by day 6 and so, did not recover their initial body weight by the end of the protocol. 
TNBS-induced rats with Severe colitis maintained a lower body weight along the entire protocol.  
In protocol 2, TNBS-induced rats with Mild colitis almost never lost weight and restarted to 
increase it from day 4 onwards. However, there was also no statistical difference between final 
and initial weight of each animal. In this protocol, TNBS-induced rats with Moderate colitis tended 
to have lower body weight than those with Severe colitis (as evidenced in AUC analysis of % body 
weight change; data not shown), and neither of these groups restarted to gain weight. 
In the previous protocol, TNBS-induced animals with Mild colitis also recovered initial weight and 
those with Moderate and Severe colitis did not16. Furthermore, as in protocol 2, animals with 
Moderate colitis tended to have higher weight loss than those with Severe colitis. 
In all protocols, no differences in body weight change between TNBS-induced rats with Moderate 
and Severe colitis were observed in any day and were generally similar. Since those with Severe 
colitis did not recover food intake, it was expected that these animals would lose more weight. 
However, when compared to those with Moderate colitis, a marked impaction of the colon 
(megacolon), and a consequent higher colonic weight, is always present in necropsy of those with 
Figure 7 - Percentage of body weight change, since day 0 (% day 0), of protocol 1 (A) and 2 (B); 
Controls (circles); Mild Colitis (squares); Moderate Colitis (triangles); Severe Colitis (inverted 
triangles). 
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Severe colitis. Therefore, it is hypothesized that the latter appear to not lose as much weight 
because the colonic weight is higher than in other groups. 
 
d. Fluid intake 
The ingestion of fluids was also measured daily. Data and statistical analysis are presented from 
day 1 onwards, in order to overcome the influence of  the preceding fasting period on fluid intake54. 
The time-course of fluid intake along protocol 1 and 2 can be found in Figure 8A and 8B, 
respectively.  
Figure 8 - Time-course of fluid intake (ml) in protocol 1 (A; water + paracetamol solution) and protocol 
2 (B; only water). Area Under Curve of fluid intake (ml.day) in protocol 1 (C) and 2 (D). Time-course 
of Paracetamol intake (ml) (E) and respective AUC (ml.day) (F), in protocol 1. Controls (circles); Mild 
Colitis (squares); Moderate Colitis (triangles); Severe Colitis (inverted triangles). *p<0.05 vs. controls; 
#p<0.05 vs. Mild Colitis; $p<0.05 vs. Moderate Colitis.  
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Generally, in both protocols, TNBS-induced rats drank more than controls. One should take into 
consideration that in protocol 1 fluid intake corresponds to the intake of both water and 
paracetamol solution. TNBS-induced rats with Mild and Moderate colitis drank more fluid than 
controls from days 3 to 6, while TNBS-induced rats with Severe colitis drank more than controls 
from day 2 until the end of the protocol. So, the AUC for fluid intake (Figure 8C) was higher in all 
TNBS-induced groups than that of controls, and that of TNBS-induced rats with Severe colitis 
was also higher than that of those with Mild colitis. The time-course of paracetamol intake in 
TNBS-induced groups showed no statistical difference (Figure 8E), although the AUC for 
paracetamol intake was lower in TNBS-induced rats with Moderate and Severe colitis than that 
observed in TNBS-induced rats with Mild colitis. Interestingly, animals with Severe colitis drank 
more fluids (water and paracetamol solution), but less paracetamol solution, than those with Mild 
colitis, which means that not only the quantity of paracetamol intake was lower in TNBS-induced 
animals with Severe colitis, but also that the relative intake of paracetamol was also lower. As 
previously discussed, we observed high variability in the intake of the paracetamol solution, 
conditioning effective analgesia that could not be guaranteed to all animals. Furthermore, the 
degree of pain might influence the animals in surpassing neophobia.  
In protocol 2, fluid intake exclusively corresponded to water intake. Since day 4 and until the end 
of the protocol, TNBS-induced rats with Moderate and Severe colitis drank more than controls 
and TNBS-induced rats with Mild colitis. This was reflected in a higher AUC for fluid intake (Figure 
8D). Furthermore, the AUC for fluid intake of TNBS-induced rats with Severe colitis was even 
higher than that for TNBS-induced rats with Moderate colitis. In the previous protocol, we also 
found this trend of TNBS-induced animals to drink more than controls, especially those with 
Severe colitis16. The higher fluid intake in TNBS-induced animals with Severe colitis might be 
explained by the development of megacolon (a necropsy finding in these animals), which can be 
responsible for dehydration. Those with Mild and Moderate colitis might have higher fluid intake 
compared to controls due to diarrhea, which is more marked in those with Moderate colitis, also 
explaining why the latter had higher fluid intake than the former. However, this parameter was not 
able to accurately predict colitis outcome. 
 
e. Fecal pellets 
We then compared both fecal pellets number and weight. Fecal pellets, especially of TNBS-
induced animals, can vary in size and consistency on the same day and animal. Thus, we decided 
to also compare their weight.  
According to weight, in protocol 1 (Figure 9A), the three categories of colitis had less fecal pellet 
weight on the 48 hours following induction, comparing to controls. Those with Mild colitis 
recovered on day 3, and fecal weight was statistically higher than that of controls on days 4 to 6. 
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Those with Moderate colitis only recovered on day 5 and surpassed the fecal weight of controls 
on days 6 and 7. When quantifying the number of fecal pellets (Figure 9B), we globally obtained 
similar results. The number of fecal pellets of the TNBS-induced animals was lower on the 48 
hours post-induction. On day 3, those with Mild colitis recovered when compared to controls, but 
was never higher in the following days. As for those with Moderate colitis, they also recovered on 
day 5, when comparing to controls, but was only higher on day 6. 
In protocol 2 (Figure 9C), animals with Mild colitis never had lower fecal weight than controls. 
Those with Moderate colitis normalized fecal pellet weight by day 6, comparing to controls. As for 
fecal pellets number (Figure 9D), the three TNBS colitis groups showed a decrease in the 48 
hours post-induction. By day 3, TNBS-induced animals with Mild colitis regained similar excretion 
as controls and the same was observed in those with Moderate colitis by day 7. 
In the previous protocol, TNBS-induced animals with Mild and Moderate colitis normalized fecal 
excretion by day 5 and 6, respectively16. In this protocol, metoclopramide was not administered 
to TNBS-induced animals. Since it improves GI motility, this might explain why TNBS-induced 
animals with Mild colitis of both protocol 1 and 2 recovered GI motility earlier. As for those with 
Moderate colitis, metoclopramide might not have had any influence in restoring GI motility, since  
it was administered many days before regaining fecal excretion. In all protocols, TNBS-induced 
animals with Severe colitis tended to have very few, if any, fecal pellets. 
 
Figure 9 - Time-course of fecal pellets weight (g) in protocol 1 (A) and 2 (C) and fecal pellets number 
(no.) in protocol 1 (B) and 2 (D). Controls (circles); Mild Colitis (squares); Moderate Colitis (triangles); 
Severe Colitis (inverted triangles). 
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The differences between the analysis of fecal pellets number and weight show that they vary in 
size and consistency, especially in TNBS-animals who restart intestinal motility. Despite these 
slight differences, the days at which TNBS-induced rats with Mild and Moderate colitis normalize 
fecal excretion, compared to controls, are generally the same. Although, in our opinion fecal pellet 
weight is more accurate, these results show that researchers can use only one of these methods 
to predict colitis outcome, according to preference. 
 
f. Monitorization of clinical signs of welfare 
Many studies fail to report (or to assess) pain and/or discomfort signs in laboratory animals65. 
For daily evaluation of animal welfare, we used two scoring systems: The Rat Grimace Scale 
(real-time side cage assessment), and the General Welfare score. The scores were given before 
any manipulation of the animals to avoid stress-induced analgesia. The use of RGS in real-time 
has shown to be reliable in rat acute pain assessment66. Real-time application can generate lower 
scores than the standard method of assessment (retrospective analysis of still images)66, 67, 
however, the latter can also result in an artificial elevation of scores due to capture of interfering 
behaviors, such as blinking66. 
In protocol 1, as expected, RGS (Figure 10A) and GW (Figure 10B) scores were higher than 
controls, after the TNBS-induction. Generally, the scores of all groups decreased over the next 
days. Curiously, on day 5 and 6 both scores of animals with Severe colitis increased and were 
Figure 10 - Time-course of Rat Grimace Scale in protocol 1 (A) and 2 (C) and General Welfare in protocol 
1 (B) and 2 (D). Controls (circles); Mild Colitis (squares); Moderate Colitis (triangles); Severe Colitis 
(inverted triangles). 
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statistically different from the other groups. Concerning protocol 2, RGS (Figure 10C) and GW 
(Figure 10D) were only able to differentiate animals with Mild colitis and animals with Severe 
colitis on day 7 and since day 5 , respectively. These results show that, although useful, the 
scoring systems used were not able to identify and predict colitis outcome. We think that further 
refinement or implementation of new scoring systems would be relevant to improve animal welfare 
and research. 
 
Part II – Non-neuronal cells mediating the contractile effect of Angiotensin II 
in the colon of control and 2,4,6-Trinitrobenzene Sulfonic Acid-induced rats  
3. Alteration in the colonic wall of control and TNBS-induced rats 
All 1-cm long colonic tissues (TDC, UDC, PC) were weighed after the functional study (wet) and 
on the next day (dry). The dry weight (Figure 11A) of all portions was higher in TNBS-induced 
animals than in controls. Furthermore, PC had lower dry weight than UDC and TDC in TNBS-
induced animals. With both the wet and dry weight, we calculated the wet-to-dry (WD) ratio 
(Figure 11B), which is considered an indirect marker of edema. TNBS-induced animals had higher 
WD ratio than controls. Also, the UDC of both controls and TNBS-induced animals had higher 
WD ratio than the correspondent PC and TDC. These results evidence the presence of structure 
alterations and edema in the colon of TNBS-induced rats. 
 
 
 
 
Figure 11 - (A) Dry weight (mg) and (B) Wet-to-Dry ratio of PC, UDC and TDC. Controls (black 
columns); TNBS-induced animals (white columns); *p<0.05 vs. controls of the corresponding 
portion. Horizontal stacked and full lines represent statistical difference (p<0.05) between selected 
portions of controls and TNBS-induced animals, respectively. 
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4. Functional study 
a. Role of the Interstitial Cells of Cajal 
T-type voltage-gated calcium (Ca2+) channels are present in the plasma membrane of ICC, and 
when activated, allow influx of calcium, which is important and necessary for their pacemaker 
activity28–30. These channels generate low-threshold calcium spikes and influence the firing 
pattern of the action potentials, besides being able to regulate smooth muscle proliferation and 
tone68. The compound NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-Benzimidazol-2-yl)propyl]-
Nmethylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropane carboxylate 
dihydrochloride)] is a selective T-type Ca2+ channel inhibitor69.   
In our study, NNC 55-0396 decreased AngII-induced contraction in all colonic portions tested, 
except for the PC of TNBS-induced animals (Figure 12), pointing to an excitatory contribution of 
ICC to the contractile effect of AngII in the rat colon (inflamed or not).  
 
 
AngII facilitates the release of neurotransmitters70, 71 and, in the tail artery of the mouse, NNC 55-
0396 reduced the facilitation of the nerve-evoked contraction caused by AngII, suggesting that T-
type Ca2+ channels mediate the facilitatory action of AngII72.  
In the mouse colon, ICC are mainly present in the proximal than in the distal colon and ICC-IM 
have been shown to be in close association with cholinergic and nitrergic motor neurons73. 
Several studies have shown that these cells are lost or damaged in many motility disorders73, 
being depleted in a TNBS model of ileitis in rats74. Loss of ICC has been reported in clinical studies 
of patients with pseudo-obstruction, chronic constipation and megacolon73. 
Taken together, our results suggest that in the uninflamed colon of the rat, ICC mediate AngII-
evoked colonic contraction, possibly by the release of an excitatory neurotransmitter, as ACh. As 
for TNBS-induced animals, we were expecting that these cells would be damaged or depleted, 
Figure 12 - Contractile response to AngII in the PC, UDC and TDC in the absence (white columns) 
and presence (black columns) of NNC 55-0396 in (A) control (PC: n=8; UDC: n=8; TDC: n=6) and (B) 
TNBS-induced animals (PC: n=5; UDC: n=5; TDC: n=4). *p<0.05 vs. AngII alone. In PC, NNC 55-
0396 (10 µM); In UDC and TDC, NNC 55-0396 (30 µM). 
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and therefore, that no difference would be found after incubation with NNC 55-0396. However, in 
the UDC and TDC (generally the most damaged areas) there was also a significant decrease of 
AngII-evoked contraction, while in the PC no effect was observed. Still, the degree of inhibition of 
AngII-contraction by NNC 55-0396 was higher in controls than in TNBS-induced animals both in 
the UDC (60.25 ± 10.49% vs 27.20 ± 8.02%, respectively, p=0.0478) and TDC (72.17 ± 6.53% 
vs 45.25 ± 9.57%, respectively, p=0.0419), probably reflecting that damage or loss of ICC. Also, 
studies which report these alterations in ICC populations in inflammation usually study one of the 
subtypes of these cells (ICC-IM; ICC-MY; ICC-SMP). In our study, the whole colon wall was 
studied and, for now, it is impossible to precise which subtype (or subtypes) mediate this 
regulatory role on AngII-evoked contraction in the rat colon. 
The expression of T-type Ca2+ channels in other cells should also be considered, namely in 
PDGFRα+ cells. However, to date no functional T-like currents of Ca2+ have been found75. 
Nonetheless, the possibility that in our study NNC 55-0396 might have also blocked T-type 
channels in other cells is not unreasonable. 
 
b. Role of the Enteric Glial Cells 
To our knowledge, our study is the first to explore the putative effect of EGC in AngII-evoked 
contraction of the rat colon. For that we used Fluorocitrate (FC), a gliotoxin known to cause 
dysfunction of the EGC without causing intestinal inflammation35. FC had no effect in colonic 
segments from controls but decreased AngII-evoked colonic contraction in the PC and UDC of 
TNBS-induced animals (Figure 13). Also, the vehicle of the Fluorocitrate solution did not alter the 
AngII-mediated colonic contraction (data not shown). 
EGC are similar to astrocytes, glial cells of the CNS. Dysfunction of these cells is related to several 
neurological diseases, such as epilepsy and amyotrophic lateral sclerosis76. These cells also 
become reactive when stimulated. This reaction can be protective if it is well regulated, however, 
a dysregulated response can be harmful and contribute to several pathologies76. In astrocytes, 
Figure 13 - Contractile response to AngII in the PC, UDC and TDC in the absence (white columns) 
and presence (black columns) of Fluorocitrate (300 µM) in (A) control (PC: n=5; UDC: n=5; TDC: n=5) 
and (B) TNBS-induced animals (PC: n=4; UDC: n=6; TDC: n=7). *p<0.05 vs. AngII alone. 
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AngII induces proliferation and neurotransmission, and activates many intracellular pathways, 
such as those related to inflammation76.  
EGC actively control neuronal functions, regulating all major gut activities through bi-directional 
communication with neurons. They are shown to be involved in neurotransmission, either by 
degradation or sequestration or by production of neurotransmitters precursors17, in immune cell 
modulation and respond to inflammation through proliferation and cytokine secretion. Additionally, 
they have been linked in the transmission of vagal anti-inflammatory signals to resident immune 
cells77. Also, parasympathetic vagal innervation activates anti-inflammatory pathways, whilst 
sympathetic vagal innervation activates pro-inflammatory pathways in EGC37. In a TNBS model 
of ileitis in rats, inflammation stimulated EGC proliferation74.  
Our results suggest that AngII-evoked contraction is not mediated by EGC in uninflamed control 
animals. Differently, they seem to mediate AngII-evoked contraction in PC and UDC of TNBS-
induced animals. This is probably a consequence of the inflammation caused by TNBS, which 
leads EGC to proliferate and become more reactive. Intriguingly, we observed no effect of FC in 
the TDC of TNBS-induced animals which was quite unexpected. It would be expected that EGC 
would also mediate AngII-evoked contraction in the TDC, since it is a region with marked 
inflammatory damage. EGC, in the inflamed colon, might mediate AngII contraction through ACh 
release, as previously proposed74. But, as for ICC, we are not able to know which subtype of EGC 
are involved in this contraction. 
 
IV. Conclusion 
In conclusion, our study allowed to establish a protocol (protocol 2) for induction of colitis in rats 
using TNBS (ethanolic solution) that favors the course of Mild and Moderate colitis, being more 
relevant for translational research and improving animal welfare (refinement). We also confirmed 
that food intake and fecal pellet excretion are the best predictors of TNBS-induced colitis outcome. 
Anticipating the category of colitis ante mortem is useful for animal welfare, data analysis and 
reproducibility of protocols. 
Taken together our functional results allow us to conclude that in controls, ICC, but not EGC, 
facilitate AngII-mediated contraction of the rat colon. Differently, in TNBS-induced animals, the 
facilitatory role of ICC seems to be attenuated while the EGC emerge as positive regulators of 
AngII-mediated contraction. 
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